Commonwealth Equity Services
HRTX icon

Commonwealth Equity Services’s Heron Therapeutics HRTX Stock Holding History

Commonwealth Equity Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.8K Buy
59,726
+300
+0.5% +$348 ﹤0.01% 4203
2025
Q4 		$77.3K Sell
59,426
-620
-1% -$766 ﹤0.01% 4139
2025
Q3 		$76K Sell
60,046
-12,074
-17% -$19.1K ﹤0.01% 4124
2025
Q2 		$149K Buy
72,120
+4,819
+7% +$9.84K ﹤0.01% 3993
2025
Q1 		$148K Sell
67,301
-925
-1% -$1.79K ﹤0.01% 3920
2024
Q4 		$104K Buy
68,226
+4,550
+7% +$7.38K ﹤0.01% 3898
2024
Q3 		$127K Buy
63,676
+6,925
+12% +$16.5K ﹤0.01% 3826
2024
Q2 		$199K Sell
56,751
-281,775
-83% -$866K ﹤0.01% 3639
2024
Q1 		$938K Buy
338,526
+10,122
+3% +$25.4K ﹤0.01% 2303
2023
Q4 		$558K Buy
328,404
+13,578
+4% +$15K ﹤0.01% 2611
2023
Q3 		$324K Buy
314,826
+16,467
+6% +$23.4K ﹤0.01% 2958
2023
Q2 		$346K Buy
298,359
+278,497
+1,402% +$497K ﹤0.01% 2928
2023
Q1 		$29 Sell
19,862
-750
-4% -$1.88K ﹤0.01% 3633
2022
Q4 		$51K Sell
20,612
-525
-2% -$1.69K ﹤0.01% 3515
2022
Q3 		$89K Buy
21,137
+4,615
+28% +$18.1K ﹤0.01% 3392
2022
Q2 		$46K Buy
16,522
+5,000
+43% +$20.1K ﹤0.01% 3498
2022
Q1 		$65K Sell
11,522
-80
-0.7% -$585 ﹤0.01% 3552
2021
Q4 		$105K Sell
11,602
-19,458
-63% -$199K ﹤0.01% 3443
2021
Q3 		$332K Sell
31,060
-371
-1% -$4.52K ﹤0.01% 2816
2021
Q2 		$487K Buy
31,431
+516
+2% +$8.21K ﹤0.01% 2489
2021
Q1 		$501K Buy
30,915
+3,706
+14% +$66.1K ﹤0.01% 2331
2020
Q4 		$575K Sell
27,209
-819
-3% -$14.2K ﹤0.01% 2054
2020
Q3 		$415K Sell
28,028
-2,067
-7% -$32.3K ﹤0.01% 2097
2020
Q2 		$442K Buy
30,095
+13,506
+81% +$222K ﹤0.01% 1972
2020
Q1 		$194K Buy
16,589
+4,339
+35% +$81.6K ﹤0.01% 2409
2019
Q4 		$287K Buy
12,250
+200
+2% +$4.42K ﹤0.01% 2356
2019
Q3 		$222K Buy
+12,050
New +$222K ﹤0.01% 2478

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Commonwealth Equity Services's HRTX Position: Q1 2026 in Review

Commonwealth Equity Services increased its Heron Therapeutics (HRTX) stake by 0.5% in Q1 2026, buying an estimated $348 and bringing the position to 59,726 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4203.

Commonwealth Equity Services first reported a position in HRTX in Q3 2019 and has held it in 27 quarters since. The position peaked at $938K in Q1 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Commonwealth Equity Services held 59,726 shares of Heron Therapeutics worth $47.8K as of Q1 2026.
  • Commonwealth Equity Services bought 300 Heron Therapeutics shares in Q1 2026, an estimated $348.
  • Heron Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4203 holding.
  • Commonwealth Equity Services first reported a position in Heron Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Commonwealth Equity Services's Heron Therapeutics position peaked at $938K in Q1 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.